Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare


Charles River Discovery




Silicon Biosystems   




  View All Sponsors 

Archived Content

Point of Care Diagnostics

Day 1 | Day 2 | Download Symposium Brochure 

The need to improve efficiency in diagnostic testing by reducing time and expense has increased the use of  rapid point-of-care testing.  This pre-conference symposium will review the technologies and trends for point-of-care diagnostics, and highlight the suitability for applications in drug development and healthcare. The symposium will cover business opportunities for both the diagnostic provider and the biotech or pharmaceutical company.  The implementation questions around companion diagnostics and why point-of-care testing is an advantageous tool that will make a difference will be addressed.

Roadmap for Accelerating Commercialization of Molecular Diagnostics  
CTCs from Bench to Bed: Streamlining from Research to Clinical Practice  
*Separate registration required.  


Sunday, February 19


7:30 am Registration and Morning Coffee

8:25 Chairperson's Opening Remarks


8:30 Business Models for Pharma in Point-of-Care and Molecular Diagnostics

Keith F. Batchelder, M.D., CEO, Genomic Healthcare Strategies

Peter S. Miller, COO, Genomic Healthcare Strategies

For decades, pharma business models have been reasonably static. The industry has done well; the blockbuster model has paid off, and hard times have been dealt with through consolidation, new research models/outsourcing research, and layoffs. This session will discuss the new problems and opportunities facing pharma caused by molecular medicine and the increased information required by doctors, payors, labs, patients, and institutions.

10:00 Networking Coffee Break with Poster Viewing

10:30 Business Models for Pharma in Point-of-Care and Molecular Diagnostics (Continued)

Keith F. Batchelder, M.D., CEO, Genomic Healthcare Strategies

Peter S. Miller, COO, Genomic Healthcare Strategies

11:00 Commentary and Industry Perspective Discussion

John McDonough, CEO, T2 Systems

Timothy T. Stenzel, M.D., Ph.D., CSO, Quidel

12:00 pm Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own


1:25 Chairperson's Remarks

1:30 Featured Presentation

Universities as Source of Point-of-Care Diagnostics Technology

Lita L. Nelsen, M.B.A., Director, Technology Licensing, Massachusetts Institute of Technology

Research institutions are a fertile source of new ideas and new intellectual property for point-of-care diagnostics, both platforms and tests. This presentation will discuss how to access these resources and how to overcome the barriers to commercialization.

2:00 Molecular Profiling of Cancer with Point-of-Care Tests

Marek Malecki, M.D., Ph.D., Associate Professor of Genetics, Genomics, and Gene Therapy; Director, Biotechnology Program, Western University of Health Sciences

2:30 Presentation to be Announced

3:00 Networking Refreshment Break with Poster Viewing


3:30 Smart Phone Optical Diagnostics

J. Matt Dubach, Bioengineering, Northeastern University

Novel fluorescent sensors provide an optical signal that corresponds to analyte target. A smart phone can be easily adapted to make fluorescent measurements and provide in vivo or in vitro concentrations measurements of targeted molecules.

3:45 Novel Electronic Assay Platform for Multiplexed Genomicand Proteomic Analysis

Hyowon Lee, Ph.D., Senior Biomedical Engineer, Technical Operations, NanoIVD, Inc.

Nanotechnology-enabled electronic assay platforms can be well-suited for point-of-care test (POCT) application. The test system is miniaturized and can be made simple to use for early disease detection testing, post therapy monitoring, and genetic and proteomic profiling of clinical samples.

4:00 Sample to Answer System for Point-of-Care Molecular Diagnostics

Michael J. Heller, Ph.D., Professor, Bioengineering and Nanoengineering, University of California, San Diego

A unique dielectrophoretic device has been developed for the isolation of cancer biomarkers (cfc-DNA), bacteria and virus from blood and other samples. Direct detection can be carried out on the device providing "seamless" sample to answer point of care diagnostics.

4:15 Using Ubiquitous Personal Glucose Meters for Portable Quantitative Detection of a Broad Range of Non-Glucose Targets

Yi Lu, Jay and Ann Schenck Professor, Chemistry, University of Illinois, Urbana-Champaign

This presentation demonstrates a novel method of using pocket-sized personal glucose meters (PGMs) to detect many targets beyond glucose, ranging from recreational drugs such as cocaine to important biological cofactors, and from disease markers such as interferon-gamma of tuberculosis to toxic metal ions.

4:30 Integrative Innovation: Bringing together Payers, Providers, and Innovators

Halle Tecco, Founder & CEO, RockHealth

4:45 Q&A with Speakers

5:00 Close of Day

Day 1 | Day 2 | Download Symposium Brochure